7Baggers
 Published on: 2025-10-03 04:25:32  newser.com Fri, 03 Oct 2025 09:25:32 GMT
 Oric Pharmaceuticals (NASDAQ:ORIC) CEO Sells $414,801.38 in Stock  MarketBeat Fri, 03 Oct 2025 01:22:17 GMT
 ORIC Pharmaceuticals Inc 4TZ Stock Analysis and Forecast  earlytimes.in Tue, 30 Sep 2025 05:48:47 GMT
 Published on: 2025-09-29 09:52:14  newser.com Mon, 29 Sep 2025 14:52:14 GMT
 Oric Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating  Investor's Business Daily Mon, 29 Sep 2025 07:00:00 GMT
 Merus NV and ORIC Pharmaceuticals Inc at Citi BioPharma Conferen  GuruFocus Sat, 27 Sep 2025 18:30:53 GMT
 Oric Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark  Investor's Business Daily Thu, 25 Sep 2025 07:00:00 GMT
 Oric Pharmaceuticals Stock Scores RS Rating Upgrade  Investor's Business Daily Wed, 17 Sep 2025 07:00:00 GMT
 stocks flashing renewed technical strength: oric pharmaceuticals  Investor's Business Daily Wed, 17 Sep 2025 07:00:00 GMT
 ORIC Virtual Meeting Scheduled by Cantor Fitzgerald  GuruFocus Tue, 16 Sep 2025 07:00:00 GMT
 ORIC: Cantor Fitzgerald Hosts Virtual Meeting on September 22  GuruFocus Tue, 16 Sep 2025 07:00:00 GMT
 published on: 2025-09-08 13:24:24  beatles.ru Mon, 08 Sep 2025 10:24:28 GMT
 layoff tracker: ac immune to cut 30% of workforce  BioSpace Fri, 05 Sep 2025 07:00:00 GMT
 guggenheim assumes coverage on oric pharmaceuticals with buy rat  GuruFocus Thu, 04 Sep 2025 14:37:12 GMT
 oric pharmaceuticals assumed with a buy at guggenheim  TipRanks Thu, 04 Sep 2025 07:00:00 GMT
 Stocks To Watch: Oric Pharmaceuticals Sees RS Rating Jump To 82  Investor's Business Daily Wed, 03 Sep 2025 07:00:00 GMT
 analysts set oric pharmaceuticals, inc. (nasdaq:oric) pt at $17.63  MarketBeat Sat, 30 Aug 2025 18:02:07 GMT
 published on: 2025-08-29 11:59:10  Newser Fri, 29 Aug 2025 16:59:10 GMT
 oric pharmaceuticals reports q2 2025 financial results  MSN Fri, 29 Aug 2025 14:44:34 GMT

ORIC Pharmaceuticals, Inc
(NASDAQ:ORIC) 

ORIC stock logo

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of ...

Full Time Employees: 60
CEO: Jacob M. Chacko  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends